RT Journal Article SR Electronic T1 Variation in ERAP2 has opposing effects on severe respiratory infection and autoimmune disease JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.11.04.22281942 DO 10.1101/2022.11.04.22281942 A1 Fergus Hamilton A1 Alexander Mentzer A1 Tom Parks A1 J Kenneth Baillie A1 George Davey Smith A1 Peter Ghazal A1 Nicholas J Timpson YR 2022 UL http://medrxiv.org/content/early/2022/11/05/2022.11.04.22281942.abstract AB ERAP2 is an aminopeptidase involved in immunological antigen presentation. Genotype data in human samples from before and after the Black Death, an epidemic due to Yersinia pestis, have marked changes in population allele frequency of the common single nucleotide polymorphism (SNP) rs2549794. This SNP in strong linkage disequilibrium with a key splicing SNP in ERAP2 (rs2248374) and this suggests that variation at ERAP2 may be relevant for protection from infection. rs2549794 is also associated with Crohn’s disease and findings imply balancing selection between infection and autoimmune disease at this locus. There have been no large-scale prospective case-control studies of variation at ERAP2 and infection.Methods This study aimed to explore the association between variation at ERAP2 and a) infection, b) autoimmune disease, and c) parental longevity as a proxy for lifespan. Genome Wide Association Studies (GWAS) of these outcomes were identified in contemporary cohorts (UK Biobank, FinnGen, and GenOMICC). Effect estimates were extracted for rs2549794 and rs2248374. Additionally, cis expression and protein quantitative trait loci (QTLs) for ERAP2 were used in Mendelian randomisation analyses.Results Across all cohorts, the T allele (minor allele frequency of 0.4-0.5) of rs2549794 showed evidence of association with respiratory infection (odds ratio; OR for pneumonia 1.03; 95% CI 1.01-1.05; p = 0.014). Effect estimates were larger in bacterial rather than viral infection and larger for more severe phenotypes (OR for critical care admission with pneumonia 1.08; 95% CI 1.02-1.14, p = 0.008, OR for death from pneumonia 1.07; 95% CI 1.01-1.12; p = 0.014). In contrast, opposing effects were identified for Crohn’s disease (OR 0.86; 95% CI 0.82-0.90, p = 8.6 × 10−9) and type 1 diabetes (OR 0.95; 95% CI 0.90-0.99, p = 0.02). No strong evidence for association was identified for sepsis. Carriage of the T allele was associated with increased age of parental death (beta in Z-scored years across both parents age at death 0.01, 95% CI 0.004-0.017, p = 0.002). Similar results were identified for rs2248374.In Mendelian randomisation analyses, increasing transcription or protein levels of ERAP2 were strongly associated with protection from respiratory infection, with opposing effects identified on Crohn’s disease and type 1 diabetes. Increased expression of ERAP2 was associated with reduced parental longevity.Conclusions Variation at ERAP2 is associated with severe respiratory infection in modern societies, with an opposing association with Crohn’s disease and type 1 diabetes. These data support the hypothesis that changes in allele frequencies in ERAP2 observed at the time of the Black Death reflect protection from infection, and suggest ongoing balancing selection at this locus driven by autoimmune and infectious diseaseCompeting Interest StatementThe authors have declared no competing interest.Funding StatementFHs time was funded by the GW4-CAT Wellcome Doctoral Fellowship Scheme. UK Biobank was funded by the Wellcome Trust, the Medical Research Council, the NIHR, and a variety of other charities (https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/our-funding). FinnGen is a public-private partnership (https://www.finngen.fi/en/access_results) funded by multiple institutions across Finland. The authors want to acknowledge the participants and investigators of the FinnGen study. AJM is a NIHR Academic Clinical Lecturer and supported by the Oxford Biomedical Research Centre (BRC). JKB gratefully acknowledges funding support from a Wellcome Trust Senior Research Fellowship (223164/Z/21/Z), UKRI grants MC_PC_20004, MC_PC_19025, MC_PC_1905, MRNO2995X/1, and MC_PC_20029, Sepsis Research (Fiona Elizabeth Agnew Trust), a BBSRC Institute Strategic Programme Grant to the Roslin Institute (BB/P013732/1, BB/P013759/1), and the UK Intensive Care Society. We gratefully acknowledge the support of Baillie Gifford and the Baillie Gifford Science Pandemic Hub at the University of Edinburgh. PGs time was funded by the Ser Cymru programme, the Welsh Government, and the EU-ERDF. NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019).  TP was funded by the Wellcome Trust Clinical Career Development Fellowship (222098/Z/20/Z). This research was funded in whole, or in part, by the Wellcome Trust [222894/Z/21/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics This work uses entirely publicly available data, so no ethical approval was required. Data are available (see Data Availability, above) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data available to replicate this analysis is publicly available. For ease, curated data is available at the authors GitHub (https://github.com/gushamilton/ERAP2) allowing ease of replication. https://github.com/gushamilton/ERAP2